Rotavirus infection and the current status of rotavirus vaccines

被引：45

作者：

Chen, Shou-Chien ^{[2
,3
]}

Tan, Lia-Beng ^{[4
]}

Huang, Li-Min ^{[5
]}

Chen, Kow-Tong ^{[1
]}

机构：

[1] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, Tainan 70101, Taiwan

[2] Da Chien Gen Hosp, Dept Family Med, Miaoli, Taiwan

[3] Ta Tung Univ, Gen Educ Ctr, Taipei, Taiwan

[4] Gods Help Hosp, Dept Urol, Chiayi, Taiwan

[5] Natl Taiwan Univ Hosp, Dept Pediat, Taipei 10016, Taiwan

来源：

JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION | 2012年 / 111卷 / 04期

关键词：

epidemiology; gastroenteritis; rotavirus; rotavirus vaccine; 1ST; 2; YEARS; ACUTE GASTROENTERITIS; CLINICAL-MANIFESTATIONS; MOLECULAR EPIDEMIOLOGY; COST-EFFECTIVENESS; POTENTIAL IMPACT; UNITED-STATES; ENTERIC PATHOGENS; RESPIRATORY-TRACT; IMMUNE-RESPONSES;

D O I：

10.1016/j.jfma.2011.09.024

中图分类号：

R5 [内科学];

学科分类号：

100201 [内科学];

摘要：

Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and of diarrheal deaths in developing countries. Current vaccines (e.g., Rotarix, GlaxoSmithKline Biologicals; RotaTeq, Merck and Company) effectively reduce rotaviral gastroenteritis, emergency department visits, and hospitalizations. The tremendous burden of rotavirus-related diarrhea in children across the world continues to drive the remarkable pace of vaccine development. This review assesses the global epidemiological and economic burden of rotavirus diseases, summarizes the relevant principles of the development of rotavirus vaccines, and presents data on the efficacy and effectiveness of currently licensed vaccines in both developed and developing countries. Copyright (C) 2012, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.

引用

页码：183 / 193

页数：11

共 125 条

[1]

Rotavirus infection in adults [J].

Anderson, EJ ;

Weber, SG .

LANCET INFECTIOUS DISEASES, 2004, 4 (02) :91-99

[2]

[Anonymous], 1999, MMWR Recomm Rep, V48, P1

[3]

Anonymous, 2008, Morbidity and Mortality Weekly Report, V57, P1255

[4]

[Anonymous], GLOB ROT SURV

[5]

ANSARI SA, 1991, REV INFECT DIS, V13, P448

[6]

Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in sub-Saharan Africa: a randomised, double-blind, placebo-controlled trial [J].

Armah, George E. ;

Sow, Samba O. ;

Breiman, Robert F. ;

Dallas, Michael J. ;

Tapia, Milagritos D. ;

Feikin, Daniel R. ;

Binka, Fred N. ;

Steele, A. Duncan ;

Laserson, Kayla F. ;

Ansah, Nana A. ;

Levine, Myron M. ;

Lewis, Kristen ;

Coia, Michele L. ;

Attah-Poku, Margaret ;

Ojwando, Joel ;

Rivers, Stephen B. ;

Victor, John C. ;

Nyambane, Geoffrey ;

Hodgson, Abraham ;

Schoedel, Florian ;

Ciarlet, Max ;

Neuzil, Kathleen M. .

LANCET, 2010, 376 (9741) :606-614

[7]

Excretion of serotype G1 rotavirus strains by asymptomatic staff: A possible source of nosocomial infection [J].

Barnes, GL ;

Callaghan, SL ;

Kirkwood, CD ;

Bogdanovic-Sakran, N ;

Johnston, LJ ;

Bishop, RF .

JOURNAL OF PEDIATRICS, 2003, 142 (06) :722-725

[8]

Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate [J].

Barnes, GL ;

Lund, JS ;

Adams, L ;

Mora, A ;

Mitchell, SV ;

Caples, A ;

Bishop, RF .

JOURNAL OF PAEDIATRICS AND CHILD HEALTH, 1997, 33 (04) :300-304

[9]

Second-year follow-up evaluation of live, attenuated human rotavirus vaccine 89-12 in healthy infants [J].

Bernstein, DI ;

Sack, DA ;

Reisinger, K ;

Rothstein, E ;

Ward, RL .

JOURNAL OF INFECTIOUS DISEASES, 2002, 186 (10) :1487-1489

[10]

Efficacy of live, attenuated, human rotavirus vaccine 89-12 in infants: a randomised placebo-controlled trial [J].

Bernstein, DI ;

Sack, DA ;

Rothstein, E ;

Reisinger, K ;

Smith, VE ;

O'Sullivan, D ;

Spriggs, DR ;

Ward, RL .

LANCET, 1999, 354 (9175) :287-290

← 1 2 3 4 5 6 7 8 9 10 →